CTLA4 and gastric cancer: The phase II INFINITY trial enrolled patients with MSI-H cT2 or greater (any N, M0) GC/GEJC (n = 15) and treated these patients with tremelimumab (anti-CTLA-4) and durvalumab (anti-PD-L1) for one cycle followed by durvalumab every four weeks for two cycles followed by surgery [70].